Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1369-1378

  Guo, Shiwei ^a,b   Jing, Wei ^b   Hu, Xiangui ^b   Zhou, Xuyu ^b   Liu, Lianjie ^b   Zhu, Minhui ^b   Yin, Fan ^a,c   Chen, Rui ^a   Zhao, Jian ^a   Guo, Yajun ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

30 kDa Tat interacting protein; epithelia mesenchymal transition; metastasis; pancreatic cancer; prognosis; Snail family members

Indexed keywords

GELATINASE B; PROTEIN TIP30; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL STRAIN PANC 1; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TISSUE MICROARRAY; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING;

EID: 84891837309     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28471     Document Type: Article

References (50)

1. Xiao H, Tao Y, Greenblatt J, et al. A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. Proc Natl Acad Sci USA 1998; 95: 2146-51.
2. Ito M, Jiang C, Krumm K, et al. TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res 2003; 63: 8763-7.
3. Lee LW, Zhang DH, Lee KT, et al. CC3/TIP30 expression was strongly associated with HER-2/NEU status in breast cancer. Ann Acad Med Singapore 2004; 33: S30-S32.
4. Tong X, Li K, Luo Z, et al. Decreased TIP30 expression promotes tumor metastasis in lung cancer. Am J Pathol 2009; 174: 1931-9.
5. Chen X, Cao X, Dong W, et al. Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma. Dig Dis Sci 2010; 55: 2219-26.
6. Liu DC, Yang ZL,. Clinicopathologic significance of minichromosome maintenance protein 2 and Tat-interacting protein 30 expression in benign and malignant lesions of the gallbladder. Hum Pathol 2011; 42: 1676-83.
7. Li X, Zhang Y, Cao S, et al. Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis. Int J Cancer 2009; 124: 713-21.
8. Jiang C, Ito M, Piening V, et al. TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem 2004; 279: 27781-9.
9. King FW, Shtivelman E,. Inhibition of nuclear import by the proapoptotic protein CC3. Mol Cell Biol 2004; 24: 7091-101.
10. NicAmhlaoibh R, Shtivelman E,. Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene 2001; 20: 270-5.
11. Zhang C, Li A, Zhang X, et al. A novel TIP30 protein complex regulates EGF receptor signaling and endocytic degradation. J Biol Chem 2011; 286: 9373-81.
12. Zhang C, Mori M, Gao S, et al. Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors. Cancer Res 2010; 70: 10224-33.
13. Zhao J, Lu B, Xu H, et al. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma. Hepatology 2008; 48: 265-75.
14. Jiang C, Pecha J, Hoshino I, et al. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin. Cancer Res 2007; 67: 3574-82.
15. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
16. Hugo H, Ackland ML, Blick T, et al. Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213: 374-83.
17. Wang BJ, Zhang ZQ, Ke Y,. Conversion of cadherin isoforms in cultured human gastric carcinoma cells. World J Gastroenterol 2006; 12: 966-70.
18. Tomita K, van Bokhoven A, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000; 60: 3650-4.
19. Toyoda E, Doi R, Koizumi M, et al. Analysis of E-, N-cadherin, alpha-, beta-, and gamma-catenin expression in human pancreatic carcinoma cell lines. Pancreas 2005; 30: 168-73.
20. Kang Y, Massague J,. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-9.
21. Huber MA, Kraut N, Beug H,. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-58.
22. Bolos V, Peinado H, Perez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003; 116: 499-511.
23. Hajra KM, Chen DY, Fearon ER,. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002; 62: 1613-18.
24. Barrallo-Gimeno A, Nieto MA,. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005; 132: 3151-61.
25. Martin TA, Goyal A, Watkins G, et al. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12: 488-96.
26. Kurrey NK, K A, Bapat SA,. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005; 97: 155-65.
27. Nieto MA,. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155-66.
28. Rhim AD, Stanger BZ,. Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog Mol Biol Transl Sci 2010; 97: 41-78.
29. Mackenzie RP, McCollum AD,. Novel agents for the treatment of adenocarcinoma of the pancreas. Exp Rev Anticancer Ther 2009; 9: 1473-85.
30. Pan JJ, Yang MH,. The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol 2011; 2: 151-6.
31. Hong SM, Li A, Olino K, et al. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol 2011; 24: 1237-47.
32. Joo YE, Rew JS, Park CS, et al. Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2002; 2: 129-37.
33. Karayiannakis AJ, Syrigos KN, Chatzigianni E, et al. Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer Res 1998; 18: 4177-80.
34. Li YJ, Meng YX, Ji XR,. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer. Hepatobiliary Pancreat Dis Int 2003; 2: 471-7.
35. Pignatelli M, Ansari TW, Gunter P, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994; 174: 243-8.
36. Kloppel G, Hruban RH, Longnecker DS, et al. Ductal adenocarcinoma of the pancreas. In:, Hamilton SR, Aaltonen LE, eds. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system, vol. 2. IARC Press, Lyon, 2000. 211-30.
37. Wang Y, Chen Y, Gao L, et al. [Expression and significance of neurogenic differentiation protein in pancreatic carcinoma]. Zhonghua Bing Li Xue Za Zhi 2012; 41: 23-7.
38. Zhao J, Ni H, Ma Y, et al. TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression. Hum Pathol 2007; 38: 293-8.
39. Hotz B, Arndt M, Dullat S, et al. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 2007; 13: 4769-76.
40. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
41. Li A, Omura N, Hong SM, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010; 70: 5226-37.
42. Winter JM, Ting AH, Vilardell F, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14: 412-18.
43. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-13.
44. Zhang K, Chen D, Jiao X, et al. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Lab Invest 2011; 91: 426-38.
45. Pecha J, Ankrapp D, Jiang C, et al. Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland. Oncogene 2007; 26: 7423-31.
46. Banerjee SK, Banerjee S., CCN5/WISP-2: a micromanager of breast cancer progression. J Cell Commun Signal 2012; 6: 63-71.
47. Graham TR, Zhau HE, Odero-Marah VA, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68: 2479-88.
48. Zhang W, Sun HC, Wang WQ, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology 2012; 143: 1641-1649.e5.
49. Peinado H, Olmeda D, Cano A., Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-28.
50. Maeda G, Chiba T, Okazaki M, et al. Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression. Int J Oncol 2005; 27: 1535-41.